drugset / Trial / NCT02766478

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

NCT02766478

Phase 2 Terminated 10 enrolled Emory University
RandomizedParallel-groupDouble-blindPrevention

Summary

Genistein is a natural supplement that comes from soy. The purpose of this study is to see if genistein has any effect on preventing or reducing heart disease and diabetes risk in men receiving Androgen Deprivation Therapy for prostate cancer. A combination of nutritional measures, blood markers and imaging tools will assess body composition, lipid levels and insulin resistance. Information from this pilot study will increase understanding of interventions which may prevent or reduce health risks during prostate cancer treatment. This project involves 24 men who will receive androgen deprivation therapy for prostate cancer.

Timeline

Start
2017-10-16
Primary completion
2021-07-23
Completion
2021-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Genistein Other / unclassified 30 mg Oral

Indications